Serabelisib, a Selective PI3Kα Inhibitor, for Slow-Flow Vascular Malformations in a Phase 3 Multicenter Single-Arm Study with Natural History Comparison
Journal of Clinical Medicine · 05.11.2026 · 15 (21) · 8624
DOI: 10.3390/jcm15218624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Noriko Aramaki-Hattori und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaken Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
Background/Objectives: Slow-flow vascular malformations, including venous malformation (VM), lymphatic malformation (LM), and Klippel–Trenaunay syndrome (KTS), are rare, symptomatic disorders with limited treatment options. This study evaluated the efficacy and safety of serabelisib, an orally available selective phosphoinositide 3-kinase α inhibitor, in these patients. Methods: This phase 3, multicenter, single-arm, confirmatory study was conducted in Japan (September 2023–June 2025). Patients aged ≥2 years received oral serabelisib once daily (100 mg for body weight ≥ 40 kg; 60 mg/m2 for
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Department of Plastic Surgery, Tonan Hospital, Sapporo 060-0004, Japan.
- Department of Radiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Department of Pediatric Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Department of Plastic and Reconstructive Surgery, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.
- Department of Pediatrics, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
ORCID-Profile: Akihiro Fujino, Tadashi Nomura, Shunsuke Sakakibara, Yoshihisa Kawakami, Junko Ochi, Motoki Akamatsu, Sadanori Akita
Förderung
- Kaken Pharmaceutical Co., Ltd.
Zitieren
APA
Aramaki-Hattori, N., Sasaki, S., Murao, N., Nozaki, T., Fujino, A., Hayashi, A., Ozeki, M., Endo, S., Akiyama, S., Nomura, T., Sakakibara, S., Kawakami, Y., Morita, A., Ochi, J., Akamatsu, M., & Akita, S. (2026). Serabelisib, a Selective PI3Kα Inhibitor, for Slow-Flow Vascular Malformations in a Phase 3 Multicenter Single-Arm Study with Natural History Comparison. Journal of Clinical Medicine, 15(21), 8624. https://doi.org/10.3390/jcm15218624
Vancouver
Aramaki-Hattori N, Sasaki S, Murao N, Nozaki T, Fujino A, Hayashi A, et al. Serabelisib, a Selective PI3Kα Inhibitor, for Slow-Flow Vascular Malformations in a Phase 3 Multicenter Single-Arm Study with Natural History Comparison. Journal of Clinical Medicine. 2026;15(21):8624. doi:10.3390/jcm15218624
BibTeX
@article{AramakiHattori2026,
author = {Aramaki-Hattori, Noriko and Sasaki, Satoru and Murao, Naoki and Nozaki, Taiki and Fujino, Akihiro and Hayashi, Ayato and Ozeki, Michio and Endo, Saori and Akiyama, Shimpei and Nomura, Tadashi and Sakakibara, Shunsuke and Kawakami, Yoshihisa and Morita, Ai and Ochi, Junko and Akamatsu, Motoki and Akita, Sadanori},
title = {Serabelisib, a Selective PI3Kα Inhibitor, for Slow-Flow Vascular Malformations in a Phase 3 Multicenter Single-Arm Study with Natural History Comparison},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8624},
doi = {10.3390/jcm15218624}
}
EUVIMED